Genmab Revenue and Competitors
Estimated Revenue & Valuation
- Genmab's estimated annual revenue is currently $7.9B per year.
- Genmab received $10.0M in venture funding in October 2014.
- Genmab's estimated revenue per employee is $4,094,203
- Genmab's total funding is $204.3M.
- Genmab's current valuation is $23.5B. (January 2022)
Employee Data
- Genmab has 1932 Employees.
- Genmab grew their employee count by 45% last year.
Genmab Competitors & Alternatives
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $7910M | 1932 | 45% | $204.3M | N/A |
#2 | $31.9M | 206 | 23% | N/A | N/A |
#3 | $3.4M | 881 | 23% | $85.7M | N/A |
#4 | $13.2M | 39 | -83% | $263.3M | N/A |
#5 | $16.1M | 104 | 16% | N/A | N/A |
#6 | $2.6M | 17 | 55% | N/A | N/A |
#7 | $8.7M | 56 | 409% | N/A | N/A |
What Is Genmab?
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications and solid tumors. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. Disclaimer: bit.ly/GENDisclaimer
keywords:N/A
$204.3M
Total Funding
1932
Number of Employees
$7.9B
Revenue (est)
45%
Employee Growth %
$23.5B
Valuation
N/A
Accelerator
Genmab News
Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. ... To develop and deliver novel...
Two years after signing a $3.9 billion alliance with Genmab to find new cancer therapies, AbbVie has said it is ready to start talking to...
AbbVie and Genmab are co-developing epcoritamab as part of the companies' broader oncology collaboration deal. "Together with our partner,...
Precision medicine company Tempus, and antibody therapeutics company Genmab announced have announced a strategic collaboration that ...
Genmab Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2014-10-27 | $10.0M | Undisclosed | Janssen Biotech Inc | Article |
Genmab Executives
| Name | Title |
|---|---|
| Jan van de Winkel | CEO/President |
| David Eatwell | Executive Vice President & Chief Financial Officer |
| Judith Klimovsky | Executive Vice President & Chief Development Officer |
| Anthony Pagano | Chief Financial Officer |
| Tahamtan Ahmadi | CMO EVP Head of Experimental Medicine |
| Denise Migliaccio | Executive Assistant to Chief Operating Officer |
| Judith Klimovsky | EVP& Chief Development Officer |
| Kay Behnke | CISO |
| Michelle Pleiter | Senior Executive Assistant to the CEO |
| Diane Schraub | Executive Assistant to Anthony Pagano, CFO Genmab |
| Jan Van | President & Chief Executive Officer |
| Jan van de Winkel | CEO/President |
| David Eatwell | Executive Vice President & Chief Financial Officer |
| Birgitte Stephensen | SVP Legal/IPR |
| Rachel Gravesen | Senior Vice President, Investor Relations and Communications |
| Martine van Vugt | SVP Strategic Initiatives |
| Judith Klimovsky | Executive Vice President & Chief Development Officer |
| Michael Bauer | Senior Vice President, Head of Operations R&D |
| Christine Zettlemoyer | SVP/ Global Head |
| Maryanne Mccarthy | Vice President, Head of Alliance Management |
| Theodora Salcedo | VP & Head Non Clinical Safety/Toxicology |
| Steve Bryant | Vice President, Head of Global Business Development |
| Scott Cenci | SVP, Information Technology and Digital |
| Tahamtan Ahmadi | CMO EVP Head of Experimental Medicine |
| Rick Jansson | Vice President |
| Melissa Thomas | VP, Program Development Lead |
| A Kate Sasser | SVP, Global Head of Translational Research and Precision Medicine, Research Ops, and Lab Management |
| Ron Graybill | Vice President, Market Access |
| John Keating | Senior Vice President, Global Commercialization |
| Julie Blaedel | Vice President Global Medical Affairs |
| Rima Bawarshi Nassar | Vice President, Head of Global Regulatory Affairs |
| Gigi Atalla | Vice President, Global head of drug safety |
| Brad Bailey | Senior Vice President & General Manager |
| Javier Pintado | Vice President, Global Marketing |
| Judith Klimovsky | EVP& Chief Development Officer |
| Dennis Nielsen | VP, Head of Procurement |
| David Satijn | Vice President, New Antibody Products |
| Judith Oprins | Vice President, Operations & Resource Management |
| Gitte Knudsen | Vice President, Head of Legal, Attorney-at-Law |
| Janine Schuurman | Senior Vice President, Head Antibody Research & Technology |
| Jesper Valbjørn | Vice President CMC |
| Claudia Corrado | Vice President, Medical, Hematology |
| Leslie Amendola | VP, US Marketing & Sales |
| Claire Blanchette | Vice President, Compound Development Team Leader |
| Michael Maldonado | VP, Head of Global Rewards |
| Cristian Lizzio | Vice President, Global HR Operations & Systems |
| Anthony Berloco | VP, Controller Genmab |
| Vibeke Didriksen | VP, Global Head of Diversity, Equity and Inclusion |
| Jan Van | President & Chief Executive Officer |
| Suzana Couto | Vice President, Head of Pathology |
| Riemke Dijkhuizen-Radersma | Vice President, Head of Global Portfolio & Project Management |
